Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2004-12-08
2009-02-17
Tsang, Cecilia (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07491705
ABSTRACT:
The present invention provides a compound represented by the formula (I):(whereinR1is a lower alkyl substituted by a lower alkoxy or a heterocyclic group, or a heterocyclic group;R2is a lower alkyl optionally substituted by a phenyl; andR3is a lower alkyl optionally substituted by a halogen, a lower alkoxy or a phenyl, or a fused polycyclic hydrocarbon group), which is well absorbed orally, exhibits durability of good blood level and has potent calpain inhibitory activity.
REFERENCES:
patent: 5444042 (1995-08-01), Bartus et al.
patent: 5514694 (1996-05-01), Powers et al.
patent: 5541290 (1996-07-01), Harbeson et al.
patent: 5610297 (1997-03-01), Powers
patent: 5650508 (1997-07-01), Powers
patent: 5763576 (1998-06-01), Powers
patent: 6150378 (2000-11-01), Chatterjee et al.
patent: 6235929 (2001-05-01), Powers
patent: 6686335 (2004-02-01), Mallamo et al.
patent: 92/12140 (1992-07-01), None
patent: 94/00095 (1994-01-01), None
patent: 98/50065 (1998-11-01), None
patent: 02/078670 (2002-10-01), None
Harbeson et al., “Stereospecific Synthesis of Peptidyl .alpha.-Keto Amides as Inhibitors of Calpain ” J. Med. Chem., 1994, 37, 2918-29.
Carragher “Calpain Inhibition: A Therapeutic Strategy Targeting Multiple Disease States,” Curr. Pharm. Des., 2006, 12, 615-38.
S. L. Harbeson et al., “Stereospecific Synthesis of Peptidyl α-Keto Amides as Inhibitors of Calpain”, J. Med. Chem., vol. 37, No. 18, pp. 2918-2929, 1994.
E. Caba et al., “Peptideyl α-Keto Amide Inhibitor of Calpain Blocks Excitotoxic Damage without Affecting Signal Transduction Events”, Journal of Neuroscience Research, vol. 67, No. 6, pp. 787-794, 2002.
K. A. Josef et al., “Potent Peptide α-Ketohydroxamate Inhibitors of Recombinant Human Calpain I”, Bioorganic & Medicinal Chemistry Letters, vol. 11, No. 19, pp. 2615-2617, 2001.
I. O. Donkor et al., “Significance of Hydrogen Bonding at the S1′ Subsite of Calpain I”, Bioorganic & Medicinal Chemistry Letters, vol. 11, No. 13, pp. 1753-1755, 2001.
R. L. DeBiasi et al., “Calpain Inhibition Protects against Virus-Induced Apoptotic Myocardial Injury”, Journal of Virology, vol. 75, No. 1, pp. 351-361, Jan. 2001.
I. O. Donkor et al., “Synthesis and Calpain Inhibitory Activity of α-Ketoamides with 2,3-Methanoleucine Stereoisomers at the P2Position”, Bioorganic & Medicinal Chemistry Letters, vol. 10, No. 22, pp. 2497-2500, 2000.
J. F. Harriman et al., “Efficacy of Novel Calpain Inhibitors in Preventing Renal Cell Death”, The Journal of Pharmacology and Experimental Therapeutics, vol. 294, No. 3, pp. 1083-1087, 2000.
K. E. Saatman et al., “Behavioral Efficacy of Posttraumatic Calpain Inhibition is not Accompanied by Reduced Spectrin Proteolysis, Cortical Lesion, or Apoptosis”, Journal of Cerebral Blood Flow and Metabolism, vol. 20, No. 1, pp. 66-73, 2000.
T. James et al., “New Inhibitors of Calpain Prevent Degradation of Cytoskeletal and Myelin Proteins in Spinal Cord In Vitro”, Journal of Neuroscience Research, vol. 51, No. 2, pp. 218-222, 1998.
Z. Li et al., “Novel Peptidyl α-Keto Amide Inhibitors of Calpains and Other Cysteine Proteases”, Journal of Medicinal Chemistry, vol. 39, No. 20, pp. 4089-4098, 1996.
K. E. Saatman et al., “Calpain Inhibitor AK295 Attenuates Motor and Cognitive Deficits Following Experimental Brain Injury in the Rat”, Proceedings of the National Academy of Sciences of the United States of America, vol. 93, No. 8, pp. 3428-3433, Apr. 1996.
R. T. Bartus et al., “Calpain Inhibitor AK295 Protects Neurons from Focal Brain Ischemia”, Stroke, vol. 25, No. 11, pp. 2265-2270, Nov. 1994.
C. Wu et al., “High-Performance Liquid Chromatographic Reversed-Phase and Normal-Phase Separation of Diastereomeric α-ketoamide Calpain Inhibitors”, Journal of Chromatography A, vol. 684, No. 2, pp. 243-249, 1994.
I. O. Donkor et al., “Design, Synthesis, Molecular Modeling Studies, and Calpain Inhibitory Activity of Novel α-Ketoamides Incorporating Polar Residues at the P1′-Position”, Journal of Medicinal Chemistry, vol. 47, No. 1, pp. 72-79, 2004.
P. Mathur et al., “Cellular Events Preceding Acetaminophen Cataractogenesis Studied by Confocal Fluorescence Microscopy”, Journal of Ocular Pharmacology and Therapeutics, vol. 19, No. 5, pp. 483-492, 2003.
W. Lubisch et al., “Benzoylalanine-Derived Ketoamides Carrying Vinylbenzyl Amino Residues: Discovery of Potent Water-Soluble Calpain Inhibitors with Oral Bioavailability”, J. Med. Chem., vol. 46, No. 12, pp. 2404-2412, 2003.
Inoue Jun
Miyashita Hiroyuki
Nakamura Masayuki
Shirasaki Yoshihisa
Bradley Christina Marchetti
Senju Pharmaceutical Co. Ltd.
Tsang Cecilia
Wenderoth , Lind & Ponack, L.L.P.
LandOfFree
Alpha-ketoamide derivative, and production method and use... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Alpha-ketoamide derivative, and production method and use..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alpha-ketoamide derivative, and production method and use... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4075703